COVID-19 UPDATE. Notable positive tone by Cuomo on NY Sunday update. Cases down. Hospitalizations down. Intubations down. Discharges up.

Today is Palm Sunday, the start of an important week and we wish blessings and health to all of you.

Governor Cuomo just completed his daily briefing and for the first time, in a long time, he was pointing to some glimmers of positive inflection.  He was not declaring the peak, not at all, but he was noting that the incoming data broadly shows what can only be described as a “break in trend”

– Daily new cases +8,327 (4/4) down from recent two days of 10,841 (4/3) and 10,482 (4/2)
– Daily deaths +594 (4/4) vs 630 (4/3) and 562 (4/2)


But there is good news on the Healthcase utilization front as well

– Total new hospitalized +574 (4/4) vs 1,095 (4/3) and 1,427 (4/2) <– HUGE decline in past 3 days
– Daily hospital discharges +1,709 (4/4) vs 1,592 (4/3) and 1,452 (4/2).
– Intubations+316 (4/4) vs 351 (4/3) and 260 (4/2).

Basically, on the hospital side, a big drop in new hospitalizations, flattening of those on ICU/intubations and more leaving the hospital.  This is probably the first daily update by Cuomo that was not littered with rising dread and urgent calls for more resources. 

Those are still needed, but it seems like NY state is trending towards/beating the optimistic case of a peak in 7 days (vs 14 to 28 of the 3 models he is using).



Daily cases is flattening and a move below 7,000 likely confirms it has peaked…
Daily cases is at 8,327 for NY state for 4/4.  This is down from the past two days (noted above) and follows a surge seen on the cases reported Friday.  Testing is way up and there is a tendency for some lumpiness.  And because of the ‘3 steps forward, two steps back’ nature of daily case counts, we realize some will be reluctant to see any inflection until we break to the downside on-trend.

– This seems to suggest one cannot be conclusive on the downside break until daily cases fall towards the sub-7,000 as this would confirm a decline in cases, rather than flattening.

COVID-19 UPDATE.  Notable positive tone by Cuomo on NY Sunday update.  Cases down. Hospitalizations down.  Intubations down. Discharges up.

Daily deaths has broken its relentless rise…
This update was what gave Cuomo pause.  He does not want to see the trend has changed, but he noted that daily deaths did not rise on 4/4, but instead was down slightly.

COVID-19 UPDATE.  Notable positive tone by Cuomo on NY Sunday update.  Cases down. Hospitalizations down.  Intubations down. Discharges up.



The trend in daily deaths was rising steadily ever since 3/24/2020, or 14 days of continuously rising reported daily deaths and even worse stories of impact on hospitals and morgues.  Lots of New Yorkers are still dying, but the fact that the uptrend is no longer exponential, is a promising development.

COVID-19 UPDATE.  Notable positive tone by Cuomo on NY Sunday update.  Cases down. Hospitalizations down.  Intubations down. Discharges up.

New Hospitalizations plunged to 574, the lowest figure since March 20th, or reversing 16 days of rising new hospitalizations.
This is very good news.  As many are aware, flattening the curve was all about making sure hospitals are not overwhelmed and that beds remain available for all critical patients.  Not only COVID-19, but anyone getting sick. Therefore, seeing the number of new hospitalizations down is at a minimum, a step in the right direction.

– again, this could be a fluke, and so it is too early to conclude.  But we can observe this is a meaningful break-in trend.

COVID-19 UPDATE.  Notable positive tone by Cuomo on NY Sunday update.  Cases down. Hospitalizations down.  Intubations down. Discharges up.


ICU intubations are flat and this remains elevated, similar to the daily deaths…
As the experience of other nations, South Korea, Italy, particularly have shown–daily cases peak well ahead of daily deaths.  As cases lead to hospitalizations, which lead to ICU/intubations and which lead to daily deaths.

– So new hospitalizations should peak before intubations peak.  And then deaths will peak.  
– The flattening here is somewhat encouraging as it suggests that NY state has a bit more time to build the critical resources needed to deal with those cases requiring ventilators.

COVID-19 UPDATE.  Notable positive tone by Cuomo on NY Sunday update.  Cases down. Hospitalizations down.  Intubations down. Discharges up.

Finally, the trend we want to see go exponential, continues to rise… Daily discharged from hospitals.
The daily discharges from hospitals are rising at an exponential rate.  This is good.  More cases are being resolved.  

– We have not heard from NY whether any treatment regimens are providing better outcomes.  And we would be most interested to see if HCL (hydroxychloroquine + z-paks) is indeed aiding in recovery.

COVID-19 UPDATE.  Notable positive tone by Cuomo on NY Sunday update.  Cases down. Hospitalizations down.  Intubations down. Discharges up.

Bottom line, this is further glimmers of hope.  NY state is the epicenter of COVID-19 in the US, with the worst outbreak and infection rate.  Based on total cases, nearly 5,000 per 1 million residents have COVID-19 or 1 in 200.  Thus, a break in the upward trajectory of infection provides a framework to see the rest of the country.

And as we noted last week, the top 8 most important states (GDP terms, that is) are mostly outperforming NY.  These 8 states are 50% of GDP.  And when NY passes its peak, the country can start to think about the economic timeline to restart the economy.

It does seem like NY state is beating the “optimistic” case for COVID-19 and potentially points to the country as a whole beating the “base case” put forth by the White House.  Currently, the White House is saying the country should brace for a horrible two weeks.  And NY state could be a bright spot during those two weeks.

We will have a more detailed update this evening.

Disclosures (show)

This research is for the clients of FS Insight only. FSI Subscription entitles the subscriber to 1 user, research cannot be shared or redistributed. For additional information, please contact your sales representative or FS Insight at fsinsight.com.

Analyst Certification (Reg AC)
Tom Lee, CFA, the research analyst denoted by an “AC” on the cover of this report, hereby certifies that all of the views expressed in this report accurately reflect his personal views, which have not been influenced by considerations of the firm’s business or client relationships. Neither I, nor a member of my household is an officer, director, or advisory board member of the issuer(s) or has another significant affiliation with the issuer(s) that is/are the subject of this research report. There is a possibility that we will from time to time have long or short positions in, and buy or sell, the securities or derivatives, if any, referred to in this research.
Conflicts of Interest

This research contains the views, opinions and recommendations of FS Insight. At the time of publication of this report, FS Insight does not know of, or have reason to know of any material conflicts of interest.

General Disclosures

FS Insight is an independent research company and is not a registered investment advisor and is not acting as a broker dealer under any federal or state securities laws.

FS Insight is a member of IRC Securities’ Research Prime Services Platform. IRC Securities is a FINRA registered broker-dealer that is focused on supporting the independent research industry. Certain personnel of FS Insight (i.e. Research Analysts) are registered representatives of IRC Securities, a FINRA member firm registered as a broker-dealer with the Securities and Exchange Commission and certain state securities regulators. As registered representatives and independent contractors of IRC Securities, such personnel may receive commissions paid to or shared with IRC Securities for transactions placed by FS Insight clients directly with IRC Securities or with securities firms that may share commissions with IRC Securities in accordance with applicable SEC and FINRA requirements. IRC Securities does not distribute the research of FS Insight, which is available to select institutional clients that have engaged FS Insight.

As registered representatives of IRC Securities our analysts must follow IRC Securities’ Written Supervisory Procedures. Notable compliance policies include (1) prohibition of insider trading or the facilitation thereof, (2) maintaining client confidentiality, (3) archival of electronic communications, and (4) appropriate use of electronic communications, amongst other compliance related policies.

FS Insight does not have the same conflicts that traditional sell-side research organizations have because FS Insight (1) does not conduct any investment banking activities, and (2) does not manage any investment funds.

This communication is issued by FS Insight and/or affiliates of FS Insight. This is not a personal recommendation, nor an offer to buy or sell nor a solicitation to buy or sell any securities, investment products or other financial instruments or services. This material is distributed for general informational and educational purposes only and is not intended to constitute legal, tax, accounting or investment advice.
The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.
Intended for recipient only and not for further distribution without the consent of FS Insight.

This research is for the clients of FS Insight only. Additional information is available upon request. Information has been obtained from sources believed to be reliable, but FS Insight does not warrant its completeness or accuracy except with respect to any disclosures relative to FS Insight and the analyst’s involvement (if any) with any of the subject companies of the research. All pricing is as of the market close for the securities discussed, unless otherwise stated. Opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, risk tolerance, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies. The recipient of this report must make its own independent decision regarding any securities or financial instruments mentioned herein. Except in circumstances where FS Insight expressly agrees otherwise in writing, FS Insight is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice, including within the meaning of Section 15B of the Securities Exchange Act of 1934. All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client website, fsinsight.com. Not all research content is redistributed to our clients or made available to third-party aggregators or the media. Please contact your sales representative if you would like to receive any of our research publications.

Copyright © 2025 FS Insight LLC. All rights reserved. No part of this material may be reprinted, sold or redistributed without the prior written consent of FS Insight LLC.